These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 22609245)
41. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276 [TBL] [Abstract][Full Text] [Related]
42. Mechanisms of disease: HDL metabolism as a target for novel therapies. Rader DJ Nat Clin Pract Cardiovasc Med; 2007 Feb; 4(2):102-9. PubMed ID: 17245404 [TBL] [Abstract][Full Text] [Related]
43. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Santos-Gallego CG; Ibanez B; Badimon JJ Biochem Pharmacol; 2008 Aug; 76(4):443-52. PubMed ID: 18547543 [TBL] [Abstract][Full Text] [Related]
44. Refocusing on use of cholesteryl ester transfer protein inhibitors. Kastelein JJ Am J Cardiol; 2007 Dec; 100(11 A):n47-52. PubMed ID: 18047853 [TBL] [Abstract][Full Text] [Related]
46. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Wierzbicki AS Curr Med Res Opin; 2005 Feb; 21(2):299-306. PubMed ID: 15802001 [TBL] [Abstract][Full Text] [Related]
47. High-density lipoprotein and progression rate of atherosclerosis in intravascular ultrasound trials. Nicholls SJ Am J Cardiol; 2009 Nov; 104(10 Suppl):16E-21E. PubMed ID: 19895940 [TBL] [Abstract][Full Text] [Related]
48. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib? Neeli H; Rader DJ Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230 [TBL] [Abstract][Full Text] [Related]
49. High-density lipoprotein cholesterol and coronary heart disease. Young CE; Karas RH; Kuvin JT Cardiol Rev; 2004; 12(2):107-19. PubMed ID: 14766026 [TBL] [Abstract][Full Text] [Related]
50. Should we take high-density lipoprotein cholesterol levels at face value? Leite JO; Fernandez ML Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929 [TBL] [Abstract][Full Text] [Related]
51. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. Michos ED; Sibley CT; Baer JT; Blaha MJ; Blumenthal RS J Am Coll Cardiol; 2012 Jun; 59(23):2058-64. PubMed ID: 22520249 [TBL] [Abstract][Full Text] [Related]
52. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Landmesser U; von Eckardstein A; Kastelein J; Deanfield J; Lüscher TF Eur Heart J; 2012 Jul; 33(14):1712-5. PubMed ID: 22696435 [No Abstract] [Full Text] [Related]
53. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Rosenson RS Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615 [TBL] [Abstract][Full Text] [Related]
57. High-Density Lipoprotein Subfractions Remodeling: A Critical Process for the Treatment of Atherosclerotic Cardiovascular Diseases. Zhang Y; Luo S; Gao Y; Tong W; Sun S Angiology; 2024 May; 75(5):441-453. PubMed ID: 36788038 [TBL] [Abstract][Full Text] [Related]
58. With statin co-administration, drugs designed to increase HDL have no impact on cardiovascular outcomes. Durrington PN Evid Based Med; 2015 Feb; 20(1):12. PubMed ID: 25249694 [No Abstract] [Full Text] [Related]
59. Pharmacogenomics in the development and characterization of atheroprotective drugs. Valanti E; Tsompanidis A; Sanoudou D Methods Mol Biol; 2014; 1175():259-300. PubMed ID: 25150873 [TBL] [Abstract][Full Text] [Related]
60. New targets of high-density lipoprotein therapy. Nicholls SJ; Nissen SE Curr Opin Lipidol; 2007 Aug; 18(4):421-6. PubMed ID: 17620859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]